Health · NZ ·
POP-DURVA: Short-Course Durvalumab Remodels the Immune Microenvironment but Rarely Produces pCR in Stage I TNB
Oncodaily · Health
Published

Read it at the source
Oncodaily↗We link out rather than republish. The reporting belongs to the publications above; the summary and the search data on this page are ours.







